PPA
AERI

Parametric Portfolio Associates’s Aerie Pharmaceuticals AERI Stock Holding History

Parametric Portfolio Associates’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.43M Buy
157,013
+56,724
+57% +$437K ﹤0.01% 2599
2021
Q4 		$704K Sell
100,289
-18,651
-16% -$195K ﹤0.01% 2933
2021
Q3 		$1.36M Buy
118,940
+6,276
+6% +$91.7K ﹤0.01% 2660
2021
Q2 		$1.8M Buy
112,664
+788
+0.7% +$13.5K ﹤0.01% 2495
2021
Q1 		$2M Buy
111,876
+5,981
+6% +$103K ﹤0.01% 2777
2020
Q4 		$1.43M Buy
105,895
+31,310
+42% +$378K ﹤0.01% 2860
2020
Q3 		$878K Sell
74,585
-17,814
-19% -$217K ﹤0.01% 3000
2020
Q2 		$1.36M Buy
92,399
+31,637
+52% +$468K ﹤0.01% 2742
2020
Q1 		$820K Sell
60,762
-110,657
-65% -$2.1M ﹤0.01% 2907
2019
Q4 		$4.14M Buy
171,419
+40,986
+31% +$849K ﹤0.01% 2198
2019
Q3 		$2.51M Buy
130,433
+61,189
+88% +$1.4M ﹤0.01% 2503
2019
Q2 		$2.05M Sell
69,244
-5,107
-7% -$197K ﹤0.01% 2659
2019
Q1 		$3.53M Buy
74,351
+6,463
+10% +$284K ﹤0.01% 2252
2018
Q4 		$2.45M Sell
67,888
-1,147
-2% -$53.8K ﹤0.01% 2446
2018
Q3 		$4.25M Sell
69,035
-11,586
-14% -$745K ﹤0.01% 2154
2018
Q2 		$5.45M Buy
80,621
+703
+0.9% +$39.3K 0.01% 1893
2018
Q1 		$4.34M Sell
79,918
-3,698
-4% -$207K ﹤0.01% 2016
2017
Q4 		$5M Sell
83,616
-7,606
-8% -$461K 0.01% 1920
2017
Q3 		$4.43M Buy
91,222
+17,624
+24% +$962K ﹤0.01% 1946
2017
Q2 		$3.87M Buy
73,598
+5,200
+8% +$242K ﹤0.01% 2006
2017
Q1 		$3.1M Buy
68,398
+3,739
+6% +$167K ﹤0.01% 2153
2016
Q4 		$2.45M Buy
64,659
+2,988
+5% +$113K ﹤0.01% 2237
2016
Q3 		$2.33M Buy
61,671
+14,677
+31% +$324K ﹤0.01% 2238
2016
Q2 		$827K Buy
46,994
+34,695
+282% +$562K ﹤0.01% 2953
2016
Q1 		$150K Sell
12,299
-18,537
-60% -$293K ﹤0.01% 3804
2015
Q4 		$751K Buy
30,836
+10,524
+52% +$246K ﹤0.01% 2995
2015
Q3 		$360K Sell
20,312
-1,640
-7% -$29.7K ﹤0.01% 2882
2015
Q2 		$387K Buy
21,952
+14,629
+200% +$268K ﹤0.01% 3427
2015
Q1 		$230K Sell
7,323
-2,987
-29% -$86.6K ﹤0.01% 3694
2014
Q4 		$301K Buy
+10,310
New +$261K ﹤0.01% 3561

Other funds holding AERI

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Parametric Portfolio Associates's AERI Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Aerie Pharmaceuticals (AERI) stake by 57% in Q1 2022, buying an estimated $437K and bringing the position to 157,013 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2599.

Parametric Portfolio Associates first reported a position in AERI in Q4 2014 and has held it in 30 quarters since. The position peaked at $5.45M in Q2 2018. 136 funds tracked by Wall St. Rank hold AERI as of Q1 2022.

  • Parametric Portfolio Associates held 157,013 shares of Aerie Pharmaceuticals worth $1.43M as of Q1 2022.
  • Parametric Portfolio Associates bought 56,724 Aerie Pharmaceuticals shares in Q1 2022, an estimated $437K.
  • Aerie Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2599 holding.
  • Parametric Portfolio Associates first reported a position in Aerie Pharmaceuticals in Q4 2014 and has held it in 30 quarters since.
  • Parametric Portfolio Associates's Aerie Pharmaceuticals position peaked at $5.45M in Q2 2018.
  • 136 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.